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Although clinical studies have yet to demonstrate clearly the use of intravenous immunoglobulin (IVIG) for
prevention of graft-versus-host disease (GVHD), their effective use in a xenogeneic mouse model has been
demonstrated. We aimed to determine the mechanism of action by which IVIG contributes to GVHD pre-
vention in a xenogeneic mouse model. NOD/LtSz-scidIL2rg/ (NSG) mice were used for our xenogeneic
mouse model of GVHD. Sublethally irradiated NSG mice were injected with human peripheral blood
mononuclear cells (huPBMCs) and treated weekly with PBS or 50 mg IVIG. Incidence of GVHD and survival
were noted, along with analysis of cell subsets proliferation in the peripheral blood. Weekly IVIG treatment
resulted in a robust and consistent proliferation of human natural killer cells that were activated, as
demonstrated by their cytotoxicity against K562 target cells. IVIG treatment did not inhibit GVHD when
huPBMCs were depleted in natural killer (NK) cells, strongly suggesting that this NK cell expansion was
required for the IVIG-mediated prevention of GVHD in our mouse model. Moreover, inhibition of T cell
activation by either cyclosporine A (CsA) or monoclonal antihuman CD3 antibodies abolished the IVIG-
induced NK cell expansion. In conclusion, IVIG treatment induces NK cell proliferation, which is essential
for IVIG-mediated protection of GVHD in our mouse model. Furthermore, activated T cells are mandatory for
effective IVIG-induced NK cell proliferation. These results shed light on a new mechanism of action of IVIG
and could explain why the efﬁcacy of IVIG in preventing GVHD in a clinical setting, where patients receive
CsA, has never been undoubtedly demonstrated.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Graft-versus-host disease (GVHD) remains a major
complication after hematopoietic stem cell transplantation
[1-4], despite the use of proper prophylactic treatments.
These treatments include a combination of immunosup-
pressive drugs that can include steroids, cyclosporine
A (CsA), methotrexate, mycophenolate mofetil, or serother-
apy by alemtuzumab or antithymocyte globulin [5-8].
These prophylactic treatments negatively impact immunedgments on page 827.
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ty for Blood and Marrow Transplantation.reconstitution, both in terms of time to recovery and effec-
tiveness; hence, making the patient vulnerable to various
illnesses and infections. Clinical studies conducted over the
past 20 years have not clearly demonstrated the therapeutic
efﬁcacy of intravenous immunoglobulin (IVIG) in the pre-
vention of GVHD. Indeed, although only a handful of these
studies have found a positive effect of IVIG treatment on
GVHD outcome [9,10], most studies concur that there does
not seem to be an advantage to IVIG treatment [11-16].
However, recent work in our laboratory has demonstrated
that IVIG was effective in decreasing the incidence of GVHD
and its related mortality in a xenogeneic GVHD (xeno-GVHD)
mouse model in which human peripheral blood mono-
nuclear cells (huPBMCs) were injected into NOD/LtSz-
scidIL2rg/ (NSG) mice, without affecting the onset or
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manized mice were injected with human cord blood CD34þ
cells [17]. We showed, in the xeno-GVHD model, that IVIG
did not modify the percentage or absolute numbers of hu-
man T lymphocytes, therefore suggesting that they
contribute to the prevention of GVHD by an immunomodu-
lating effect.
Evidence arose in the literature that natural killer (NK)
cells may play important role in GVHD prevention [18-22]. In
the present manuscript, we investigated the effect of IVIG on
NK cells and unexpectedly observed that IVIG induced an
expansion of NK cells that were required for the IVIG-
induced inhibition of GVHD in our xeno-GVHD model.
MATERIALS AND METHODS
Mice
NSG mice were obtained from the Jackson Laboratory (Bar Harbor, ME)
and bred in the animal care facility at the CHU Sainte-Justine Research
Centre. Mice were housed under speciﬁc pathogen-free conditions in sterile
ventilated racks. All procedures were previously approved by the Institu-
tional Committee for Good Laboratory Practices for Animal Research, as per
our research protocols (SST08-77, SST09-22, SST10-40, and E466). Irradiated
mice were given either .08 mg/mL ciproﬂoxacin (Sandoz, Boucherville, QC,
Canada) or .20 mg/mL enroﬂoxacin (Bayer Inc., Montreal, QC, Canada) in
their drinking water.
Xenogeneic Model of GVHD
Leukapheresis was performed using blood samples from 6 healthy do-
nors after informed written consent. huPBMCs were isolated using a Ficoll-
Paque PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) density
gradient. After sublethal 2 to 3 Gy irradiation, 7- to 9-week-old NSG mice
were injected intraperitoneally (i.p.) with 107 huPBMCs on day 0 and treated
i.p. once a week from day -1 until day þ42 with either PBS (Invitrogen,
Burlington, ON, Canada) or IVIG (Gamunex 50 mg/mouse; Talecris Bio-
therapeutics, Research Triangle Park, NC). For some experiments, as indi-
cated in the results section, huPBMCswere injected intravenously (i.v.). Mice
treated with monoclonal antihuman CD3 antibodies (OKT3; Bio X Cell, West
Lebanon, NH; .05 mg/mouse) were injected i.p. on days þ1, þ3, and þ5,
while mice treated with CsA (Novartis, Dorval, QC, Canada; .375 mg/mouse)
were injected i.p. daily from day 0 until dayþ23 [17]. NK cells were depleted
from huPBMCs using CD56MicroBeads (Miltenyi Biotec, Auburn, CA) per the
manufacturer’s recommendations. T celledepleted huPBMCs were obtained
by sorting CD3- cells on a BD FACSAriaI (BD Biosciences, Mississauga, ON).
Assessment of GVHD
Mice were evaluated in a blinded fashion every other day using a GVHD
assessment scale and GVHD diagnosis was given as previously described
[17,23]. Survival was noted daily for each experimental group. Mice were
sacriﬁced when speciﬁc clinical endpoints were reached, as previously
described [17]. A volume of 100 mL of peripheral blood was drawn weekly
from the saphenous vein and collected in heparin-coated Microvettes
(Sarstedt Inc., Montreal, QC, Canada). Circulating cells were analyzed by ﬂow
cytometry to determine the lymphocyte populations.
Flow Cytometry
Human and murine cell populations were analyzed by ﬂow cytometry.
Fluorescein isothiocyanate (FITC) antimouse CD45, FITC antihuman CD16,
FITC antihuman HLA-DR, R-phycoerythrin (PE) antimouse CD45, PE anti-
human CD56, PE antihuman CD337 (NKp30), PE antihuman CD25, allo-
phycocyanin (APC) antihuman CD19, APC antihuman CD45, APC antihuman
NKG2D, Alexa Fluor 700 antihuman CD56, APC-Cy7 antihuman CD45, APC-
Cy7 antihuman CD3, APC-Cy7 antihuman CD14, V500 antihuman CD3 (BD
Biosciences), peridinin-chlorophyll-protein complex antimouse CD45,
peridinin-chlorophyll-protein complex antihuman CD45, APC antihuman
CD16, Paciﬁc Blue antihuman CD3 (BioLegend, San Diego, CA), PE antimouse
CD115, PE-Cy7 antimouse CD11c (eBioscience, San Diego, CA), and PE-Texas
Red antihuman CD45 (Invitrogen) antibodies were used to identify cell
populations, along with DAPI (40 ,6-diamidino-2-phenylindole; Sigma-
Aldrich Canada Ltd., Oakville, ON, Canada) or 7-aminoactinomycin D for
dead cell discrimination (BD Biosciences). CountBright beads were added
before ﬂow cytometry acquisition to determine the absolute number of cells
in each sample (Invitrogen). Samples were acquired on a BD FACSAriaI or BD
LSRFortessa ﬂow cytometer and analyzed using FACSDiva software (BD
Biosciences).Cell Cycle Analysis
For bromodeoxyuridine (BrdU, Sigma) labeling and staining, xeno-
GVHD mice received an initial i.p. injection of 1 mg BrdU on day þ10 of
the experiment, followed by 3 days of BrdU in the drinking water (.8 mg/
mL). On dayþ14, mice were sacriﬁced and BrdU incorporationwas detected
by ﬂow cytometry with the FITC-BrdU ﬂow kit (BD Biosciences).
Apoptosis Assay
Apoptosis wasmeasured using the annexin V-binding assay (Invitrogen)
according to themanufacturer’s instructions. Brieﬂy, cells werewashedwith
PBS and resuspended in 100 mL of 1 annexin V-binding buffer. FITC-labeled
annexin V and 7-aminoactinomycin D were added to each sample and
subsequently analyzed by ﬂow cytometry.
Cytotoxicity Assay
Spleenswere collected from xeno-GVHDmice on dayþ10 after injection
and splenocytes were obtained after disruption of the organ in PBS on a
70 mmcell strainer. Mononuclear cells were isolated from the splenocytes on
a Ficoll-Paque PLUS density gradient and their cytotoxic activity was
measured in a standard 4-hour chromium release assay. A total of 106 K562
cells were incubated for 45 minutes with 50 mCi 51Cr at 37C. Triplicate of
effector to target cell ratios of 5:1, 10:1, 20:1, and 40:1 were plated in a ﬁnal
volume of 200 mL in U-bottom 96-well plates (Corning Inc., Corning, NY).
After a 4-hour incubation at 37C, 100 mL of supernatant was transferred to
borosilicate glass tubes (Kimble Chase, Vineland, NJ) and the counts per
minute (cpm) were measured in a gamma counter (PerkinElmer, Waltham,
MA). Cytotoxic activity was calculated according to the following formula:
percent speciﬁc lysis ¼ ([cpm testecpm spontaneous release]/[cpm
maximum release e cpm spontaneous release])  100.
Statistics
Results were analyzed using GraphPad Prism 5.0 (GraphPad Software
Inc., La Jolla, CA). Incidence and survival statistics were determined using the
Mantel-Cox (log-rank) test. Elsewhere, the Mann-Whitney test or Kruskal-
Wallis test was used with a threshold for signiﬁcance set at P  .05.
Figures show means  SEM.
RESULTS
Weekly IVIG Treatment in Xeno-GVHD Mice Induces NK
Cell Expansion
We have previously demonstrated that mice injected i.p
with 107 huPBMCs and treated weekly with 50 mg IVIG i.p.
showed a decreased incidence of xeno-GVHD and increased
survival, without affecting their level of circulating T lym-
phocytes [17]. To understand the mechanism of action of IVIG
in our model, we assessed the presence of other cell pop-
ulations in the peripheral blood of mice. We conﬁrmed our
previous result on T lymphocytes [17] and observed that the
activation status of T cells was not affected by IVIG, as deter-
mined by HLA-DR and CD25 expression (data not shown).
Importantly, we observed a signiﬁcant increase in the per-
centage (Figure 1A) and absolute number (Figure 1B) of
circulating NK cells (Figure 1C) in the peripheral blood of IVIG-
treated mice compared with the PBS-treated control group.
This increase in NK cells reached amaximumby dayþ14, after
which the number of NK cells in the peripheral blood started
to decrease, reaching a stable level by day þ21 that remained
unchanged throughout the rest of the experiment, despite
continuous weekly IVIG injections (Figure 1A,B).
Phenotype and Function of IVIG-induced NK Cells
We next analyzed whether the IVIG-induced NK cell in-
crease was due to the proliferation of NK cells rather than to
reduced cell death. We ﬁrst performed a BrdU incorporation
assay (Figure 2A). As shown in Figure 2B, over 20% of NK cells
were in the S phase of the cell cycle on day þ14 in the blood,
spleen, and liver. By assessing viability and apoptosis of NK
cells, we observed that over 80% of NK cells in the peripheral
bloodwere viablewhereas NK cells weremostly nonviable in
the organs, as more than 80% and 60% of the NK cells were
Figure 1. Weekly IVIG treatment induces expansion of human NK cells. PBMC
from PBS- (n ¼ 10, empty circles) and IVIG-treated mice (n ¼ 10, ﬁlled circles)
were analyzed for percent (A) and (B) absolute numbers of NK cells. (C) PBMC
isolated from PBS- and IVIG-treated mice and gated on hCD45þ cells were
analyzed for CD3 and CD56 expression. Representative data of contour plots
on day þ14.
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Together, these results strongly suggest that the IVIG-
induced expansion of NK cells was mediated by active pro-
liferation rather than by prolonged survival of the NK cells.
To phenotype the IVIG-induced NK cells, we analyzed the
expression of NK cell activation markers CD25, NKG2D,
NKp30, and CD16 by ﬂow cytometry (Figure 3A). With the
exception of CD25, all of the activation markers were
homogenously expressed on NK cells in the blood as well as
those found in various organs, suggesting that IVIG not only
induced the proliferation but also the activation of NK cells.
To conﬁrm the activated phenotype of IVIG-induced NK cells,
we performed a 51chromium release assay using K562 as the
target cell line. Splenocytes collected on day þ10 from
IVIG-treated mice demonstrated cytotoxic activity against
the K562 cells. This cytotoxic activity, although very modest,
was signiﬁcantly higher than that of splenocytes from PBS-
treated control mice, which showed no detectable cytotoxic
activity (Figure 3B).
The Presence of NK Cells Is Required for IVIG-mediated
Prevention of Xeno-GVHD in Mice
Because weekly IVIG treatment led to the expansion of NK
cells in vivo, we investigated the role of the NK cells in IVIG-mediated reduction of xeno-GVHD by injecting NK cellede-
pleted huPBMCs (>99% purity) into mice that were treated
weekly with PBS or IVIG. As expected, no NK cells were
observed in the peripheral blood of mice at any time during
the experiment (data not shown). As previously demonstrated
[17], in xeno-GVHDmice injectedwith total huPBMCs, weekly
treatment with IVIG signiﬁcantly decreased the incidence of
GVHD (P¼ .003; Figure 4A) and led to greater survival (P¼ .04;
Figure 4B) compared with PBS-treated control mice. The
absence of NK cells in the graft did not affect the development
of GVHD, as demonstrated by the similar GVHD incidence and
mortality rate between PBS-treated mice injected with total
huPBMCs and with NK celledepleted huPBMCs (incidence:
P ¼ .91; mortality: P ¼ .74). However, IVIG had no protective
effect against GVHD incidence and mortality in mice that
received NK celledepleted huPBMCs, when compared with
PBS-treated mice (Figure 4). Together, these results suggest
that NK cells are required for the IVIG-mediated GVHD pre-
vention in our model.
Importance of IVIG Route of Administration
In our model of xeno-GVHD, IVIG and huPBMCs were
both injected within a 24-hour period via the i.p. route, 2
parameters that could potentially account for the expansion
of NK cells. First, we modiﬁed the route of injection of
huPBMCs from i.p. to i.v., without altering that of IVIG. We
and others [24] have demonstrated that i.v. injection of
huPBMCs in this mouse model effectively generated xeno-
GVHD (data not shown). When IVIG was administered i.p.
and huPBMCs i.v., no NK cells could be detected in the pe-
ripheral blood or organs of the treated mice and all mice
died of xeno-GVHD (Figure 5A and data not shown).
Therefore, to be efﬁcient, IVIG must be injected by the same
route of administration as huPBMCs. These results suggest
that IVIG and huPBMCs need to interact to induce the
expansion of NK cells and protect the treated mice from
developing GVHD. We next assessed the effect of the timing
of the initial IVIG injection on NK cell expansion by
designing experimental groups where the initial IVIG
treatment was administered on days -1 andþ7 with respect
to the huPBMCs injection. Thereafter, IVIG treatment was
given weekly and NK cell expansion was evaluated. As
shown in Figure 5B, the delay of the initial IVIG treatment
signiﬁcantly (P ¼ .04, P ¼ .04, and P ¼ .01 for days þ7, þ14,
and þ21 after injection, respectively) decreased the per-
centage of circulating NK cells. Together, these results sug-
gest that IVIG must be administered early and close to the
time of huPBMCs administration to allow for NK cell
expansion. Furthermore, the reduction of circulating NK
cells caused by the delay in initial IVIG treatment induced a
higher incidence of GVHD in mice (Figure 5C, initial IVIG
treatment at day-1 compared to day þ7: P ¼ .02).
Activated T Cells Are Required for IVIG-induced NK Cell
Expansion
We previously showed that CsA and OKT3 both inhibited
GVHD in our model [17]. To determine if IVIG acted directly
on NK cells or via T cells, IVIG-treated mice were given either
CsA to inhibit T cell activation, or OKT3 to deplete T cells
in vivo. Interestingly, we noted that the presence of T cells
was necessary for IVIG-induced NK cell expansion to occur,
as no NK cells were detected in the OKT3-treated mice
(Figure 6). Furthermore, no NK cells were detected in the
CsA-treated mice, thereby suggesting that the activation of T
cells was also mandatory for the IVIG-induced expansion of
Figure 3. IVIG induce the functional activation of human NK cells. (A) NK
cellespeciﬁc activation markers were analyzed on day þ14 on cells isolated
from the blood (white bars), spleen (dotted bars), and liver (black bars) of
IVIG-treated mice (n ¼ 5). (B) Splenocytes collected on day þ10 from PBS-
(empty circles) and IVIG-treated mice (ﬁlled circles) were used in cytotoxic
assay against the K562 cells. Representative data (from 1 of 4 independent
experiments) on cytotoxicity assay after a standard 4-hour 51chromium
release assay.
Figure 4. IVIG treatment reduces the incidence of GVHD and mortality in mice
injected with huPBMCs but not with NK-depleted huPBMCs. (A) Incidence of
GVHD and (B) survival of PBS-treated and IVIG-treated (empty circles, n ¼ 23;
ﬁlled circles; n ¼ 22, respectively) huPBMCs-injected mice, and PBS- and IVIG-
treated NK-depleted (empty squares; n ¼ 7; ﬁlled squares; n ¼ 6, respectively)
huPBMCs-injected mice.
Figure 2. Phenotype and function of IVIG-induced NK cells. (A) IVIG-treated xeno-GVHD mice were injected with 1 mg BrdU on day þ10, and received additional
BrdU in their drinking water until being sacriﬁced on day þ14. Cells were collected from the blood, spleen, and liver of IVIG-treated mice and analyzed by ﬂow
cytometry for BrdU incorporation and expression of annexin V and 7-AAD. Because no NK cells were found in blood or tissues of PBS-treated mice, this experimental
group was not included in the ﬁgure. Representative data of contour plots on day þ14 (left quadrant: subG0-G1 phase; lower left quadrant: G0-G1 phase; upper
quadrant: S phase; lower right quadrant: G2-M phase). (B) Percent of NK cells in the S phase of the cell cycle (n ¼ 6). (C) Analysis of NK cells of blood and different
tissue origin on day þ14 for apoptosis (n ¼ 5; black bars: live cells; dotted bars: early apoptotic cells; white bars: late apoptotic cells).
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Figure 5. IVIG must be administered by the same route and the same day as
huPBMCs for effective expansion of human NK cells. (A) IVIG were adminis-
tered i.p. and huPBMCs i.v. and PBMC on day þ14 were isolated from PBS-
(n ¼ 10) and IVIG-treated (n ¼ 10) mice, gated on hCD45þ cells, and analyzed
for CD3 and CD56 expression. Representative data of contour plots on dayþ14.
(B) Expansion of NK cells with initial IVIG treatment on day 1 (n ¼ 33),
day þ7 (n ¼ 6) (P ¼ .04, .04, and .01 at days þ7, þ14, and þ21 post-injection,
respectively). (C) Incidence of GVHD in mice treated with IVIG from day -1
(dotted line; n ¼ 33) or þ7 (line; n ¼ 6); P ¼ .02.
J. Gregoire-Gauthier et al. / Biol Blood Marrow Transplant 21 (2015) 821e828 825NK cells (Figure 6). To further validate this result, we injected
T celledepleted huPBMCs (>98% purity) in IVIG-treatedmice
and observed that despite weekly IVIG treatment, these mice
showed absolutely no NK cell expansion (Figure 6).
Mechanism of Action of IVIG-induced NK Cells in GVHD
Prevention
NK cells are known to reduce GVHD [18-22] and it has
been suggested that this is mediated through an effect on T
cells, either by regulating T cell proliferation [25-27] or
increasing T cell apoptosis [28], or through reduction ofFigure 6. T cells are required for IVIG-induced NK cell expansion in vivo. NK
cell expansion was analyzed in IVIG-treated control (ﬁlled circles; n ¼ 10),
OKT3-treated (empty squares, n ¼ 4), CsA-treated (ﬁlled triangles, n ¼ 7), or T
celledepleted huPBMCs-injected mice (empty circles; n ¼ 3).antigen-presenting cells, thus affecting T cell activation [18-
22,29]. Towards this end, we ﬁrst assessed the possible
antiproliferative and proapoptotic effects on T cells. BrdU
incorporation and annexin V assays showed that the pres-
ence of IVIG-induced NK cells in mice neither affected the
proliferation (Figure 7A) nor the apoptosis (Figure 7B) of
donor T cells in the blood, spleen, and liver of xeno-GVHD
mice that were sacriﬁced at day þ14. Next, we tested the
possibility that the IVIG-induced NK cells could contribute to
reduce the pool of antigen-presenting cells [25-27]. Mice
injected with total huPBMCs or NK-depleted huPBMCs and
treated weekly with either PBS or IVIG were sacriﬁced at
day þ14, where human and murine antigen-presenting cells
were enumerated in the blood, spleen, and liver. We did not
observe any reduction of the number or percent of both
human and murine antigen-presenting cells in IVIG-treated
mice when compared with PBS-treated mice (data not
shown). These results suggest that, in our model, the IVIG-
induced NK cells prevent GVHD development neither by
affecting the proliferation and apoptosis of T cells nor via the
destruction of host or donor antigen-presenting cells.
DISCUSSION
We have previously demonstrated that weekly IVIG
treatment reduced the incidence of GVHD and its related
mortality in a xenogeneic mouse model of acute GVHD
[17]. Here, we demonstrate that in the same model, IVIG
induce the expansion of NK cells, representing over 30% of
circulating lymphocytes by day þ14, and that this expan-
sion is required for the inhibition of GVHD by IVIG. This
expansion was due to NK cell proliferation and not to a
reduction of NK cell apoptosis, and it was T cell dependent.
In addition, we show that the delay of the initial admin-
istration of IVIG resulted in the failure of NK cell expansion,
as did injecting IVIG and huPBMCs by different routes of
administration. In both cases, the lack of expansion of the
NK cell population in vivo was accompanied by a failure to
prevent the development of GVHD. All together, our results
conﬁrm that IVIG plays a genuine immunomodulatory role
in GVHD prevention, rather than simply acting as a
plasma-ﬁlling agent, as demonstrated by the absence of
GVHD prevention in IVIG-treated mice injected with NK
celledepleted huPBMCs. Also, because in vitroeactivated
and ampliﬁed NK cells obtained by the NK cell activation
and expansion system (NKAES) method [30] did not inhibit
GVHD in our model (data not shown), this suggests that
IVIG is necessary for the prevention of GVHD by NK cells in
our model.
In an MHC-mismatched murine model of GVHD, infusion
of low doses of both invariant and noninvariant NKT cells
have successfully managed to reduce GVHD without sup-
pressing the proliferation of T cells responsible for the onset
of GVHD [31]. In our model, IVIG reduced the incidence of
GVHD, without suppressing the proliferation of donor T cells
(Figure 7). Thus, it is possible that donor NKT cells are
involved in the IVIG-mediated prevention of GVHD observed
in our model. Furthermore, because NK cell depletion in our
experiments was achieved through depletion of CD56þ cells,
NKT cells from the huPBMCs would, therefore, have equally
been depleted, which could contribute to the explanation of
the loss of GVHD prevention in such conditions.
Many potential target mechanisms have been suggested
to explain the immunomodulatory function of IVIG [32].
Possible mechanisms include the downregulation of proin-
ﬂammatory cytokines and adhesionmolecules, the reduction
Figure 7. Analysis of T cell proliferation and apoptosis in vivo in xeno-GVHD mice. A BrdU incorporation and an annexin V assays were performed on cells from the
blood, spleen, and liver of xeno-GVHD mice that were sacriﬁced at day þ14. (A) Proliferation, assessed by the percentage of T cells in the S phase of the cell cycle and
(B) apoptosis of T cells in vivo in PBS-treated (n ¼ 5, white) and IVIG-treated (n ¼ 6, black) mice.
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(FcRn), the blockade of activating Fc receptors, the upregu-
lation of FcgRIIB [33], and immunomodulation by sialylated
IgG [34]. Until recently, the possible role of NK cells in
mediating the immunomodulatory effect of IVIG had never
been mentioned. On the contrary, it was suggested that for
preventing miscarriage, IVIG could act by inhibiting NK cells
[35-44]. However, very recently, Chong et al. [45] elegantly
demonstrated that NK cells are necessary for the prevention
of experimental autoimmune encephalomyelitis (EAE) by
IVIG treatment. They showed that IVIG could not prevent
EAE in NK-depleted mice and that adoptive transfer of Ig-
treated NK cells into these mice rescued the protective ef-
fect against development of EAE. Furthermore, the effect of
IVIG on NK cells led to an increase in CD4þFoxp3þ regulatory
T cells, which were responsible for the protective effect on
EAE. In our model, the presence of IVIG-induced NK cells did
not affect the regulatory T cells [17]. Besides direct killing of
autologous T cells [28], NK cells could interfere with T cell
activation and proliferation [25]. However, both of these
mechanisms are unlikely involved in the NK cellemediated
prevention of GVHD in our model, as we did not observe any
modiﬁcation in the T cell proliferation and activation.
Furthermore, we observed proliferation of NK cells in our
model, whereas Chong et al. do not mention whether NK
cells were increased by IVIG or not. To our knowledge, the
only already published situation where NK cell proliferation
has been reported after IVIG is in Kawasaki disease [46].
Therefore, although both we and Chong et al. demonstrate
that IVIG mediate immunomodulation through NK cells, it
seems that the mechanisms by which NK cells modulate the
GVHD in our model and EAE in their model are different.
In addition to the proliferation of NK cells, we showed
that IVIG induced their activation, as demonstrated
by the expression of the activation markers CD25, NKG2D,
NKp30, and CD16. NKG2D and NKp30 are potent activating
receptors involved in cytolysis [47-49], and CD16 is
commonly used to discriminate the cytokine-producing
NK cells (CD56brightCD16) from the cytotoxic NK cells
(CD56dimCD16þ) [50]. IVIG could potentially bind via their Fc
to the activating FcgRIIIa present on the CD56dimCD16þ NKcells, leading to their activation and enabling them to exhibit
mechanisms of degranulation, phagocytosis, and antibody-
dependent cell-mediated cytotoxicity [51]. It is of note that
many studies have reported a decrease in NK cell activity
after IVIG treatment, notably by inducing a functional
impairment of CD56dimCD16þ NK cells [35,36,38-40,52].
Interestingly, in our model not only do the IVIG-induced NK
cells have an activated phenotype, they also show modest
cytotoxicity against the K562 target cell line. An undisputed
limitation in this experiment was the number of splenocytes
that were isolated from themice. A huge number of micewas
necessary to achieve the effector to target cell ratios used in
this experiment, and for this reason it was impossible to
reach higher ratios and demonstrate a greater cytotoxic ac-
tivity of IVIG-induced NK cells. Also, one cannot rule out that
GVHD suppression could be responsible for at least a part of
NK cell proliferation, although no NK cell proliferation was
observed in mice treated with CsA or OKT3.
As mentioned, clinical studies on Kawasaki disease re-
ported that IVIG could partially reverse an initially low
number of NK cells [53] and contribute to both their
expansion and activity, as well as to an increase in the
number of circulating CD16þ cells [46]. However, many
clinical studies where IVIG were given to women suffering
from recurrent spontaneous abortions, a noninﬂammatory
condition, reported the opposite results, ie, decreased NK cell
cytolytic activity and/or decreased number or percentage of
circulating NK cells in treated women [35-39,41-44]. These
discrepancies could be explained by the various conditions in
which IVIG are used and, particularly, the existence or not of
an inﬂammatory state. The observed effect of IVIG on NK
cells, therefore, seems to be dependent on the inﬂammatory
condition and cytokine milieu.
Speciﬁcally, we have demonstrated that T cells are
necessary for NK cell proliferation. Our data suggest that T
cells play a supporting role in NK cell survival. Indeed, as
previously demonstrated, human proinﬂammatory cyto-
kines are produced in our xeno-GVHD model [17], which we
hypothesize are necessary for NK cell survival and prolifer-
ation in the murine environment, particularly IL-2 and IL-15
[54,55]. Potentially, reduced plasma levels of IL-2 and IL-15
J. Gregoire-Gauthier et al. / Biol Blood Marrow Transplant 21 (2015) 821e828 827observed in the IVIG-treated mice [17] could be related to
increased uptake of these cytokines by NK cells.
The creation of an inﬂammatory milieu, reminiscent of
Kawasaki disease, could explain why we observe NK cell
expansion upon IVIG treatment and why, in the absence of T
cells, no NK cells are detected (Figure 6). In the clinical
setting, patients at risk for GVHD always receive CsA, an in-
hibitor of T cell activation. Therefore, there is a distinct pos-
sibility that patients in an immunosuppressed state would
not beneﬁt from IVIG treatment to prevent GVHD, and this
could explain why previous clinical studies have failed to
demonstrate a role for IVIG in GVHD prevention [11-16].
In summary, our data indicate that weekly treatment of
xeno-GVHD mice with IVIG leads to the expansion and acti-
vation of NK cells that play a critical role in reducing the
incidence andmortalityofGVHD. Furthermore, in theabsence
of NK cells, IVIG provides no beneﬁcial effect against xeno-
GVHD in our model. More importantly, our results highlight
the importance of the presence of Tcells for successful NK cell
proliferation upon IVIG treatment, which could explain why
clinical protocols involving IVIG do not yield the same results
as seen in our xeno-GVHD mouse model.
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